Some aspects of the drug therapy of type 2 diabetes mellitus in overweight patients
DOI:
https://doi.org/10.22141/2224-0721.15.5.2019.180046Keywords:
type 2 diabetes mellitus, glycemic control, anti-diabetic drugs, reviewAbstract
This is a mini-review of recent publications on hypoglycemic drugs applicable to the treatment of type 2 diabetes mellitus in overweight patients. The article discusses the following topics: the influence of medications on body weight, function of pancreatic beta-cells, indications for the intensive glycemic control and medication costs. Glucagon-like peptide-1 receptor agonists stimulate insulin secretion, slow down gastric emptying, cause satiety and reduce food intake, contributing to the weight loss. The sodium glucose cotransporter 2 inhibitors suppress the renal glucose reabsorption, lower blood pressure and contribute to a reduction of body weight. A body weight reduction should be awaited also from inhibitors of intestinal alpha-glucosidase. Hypoglycemic effects of the two latter drug classes are unrelated to the stimulation of insulin secretion by beta cells. It is known that the secretory function of pancreatic islets can be exhausted by a prolonged stimulation. In conclusion, the goals of glycemic control need to be individualized based on the age, prognosis, presence of cardiovascular disease, and risk of hypoglycemia. Appropriate management of hypertension, dyslipidemia, and other cardiovascular risk factors are of importance for the prevention of complications in type 2 diabetes mellitus.Downloads
References
Dedov II, Shestakova MV. Type 2 diabetes mellitus: from theory to practice. Moscow: MIA; 2016. (in Russian).
Dreval AB, Misnikova IV, Starostina EG, et al. Practice of Diabetology. Moscow: GEOTAR-Media; 2018. (in Russian).
Dedov II, Shestakov MV, Aleksandrov AA, et al. Complication of diabetes mellitus: treatment and prevention. Moscow: MIA, 2017. (in Russian).
Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100. https://cardiab.biomedcentral.com/articles/10.1186/s12933-015-0260-x
Galstian GR. The concervator’s viewpoint. Effective Pharmacotherapy. 2018;(12):52-53. (in Russian).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 S.V. Jargin
This work is licensed under a Creative Commons Attribution 4.0 International License.